On June 18, 2024, Silk Road Medical announced that it entered into a definitive agreement to be acquired by Boston Scientific Corporation for a purchase price of $27.50 per share, reflecting an aggregate equity value of approximately $1.26 billion. Silk Road Medical is a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). Wilson Sonsini Goodrich & Rosati advised Silk Road Medical on the transaction.

The team that advised Silk Road Medical included:

M&A
Robert Ishii
Remi Korenblit
Dennise Martinez
Ava Munson
Michael Anthony

Employee Benefits and Compensation
Sriram Krishnamurthy
Michael Klippert
Lori Howey
Jason Chan

Technology Transactions
Alex Key
Isaiah Loya
Kimberly Parry

Antitrust
Jamillia Ferris
Brendan Coffman
Kimberley Biagioli
Michael McLaughlin

Corporate Finance
Dana Hall
Joseph Catapano

Privacy and Cybersecurity
Matt Staples
Daniel Chen
Dantam Le
Hale Melnick
Chany Kim

Employment Law
Jason Storck
Aren Balabanian
Ryan Gribbin-Burket

Healthcare Regulatory
Andrea Linna
Eva Yin

Real Estate
Susan Reinstra
Martin Sul
Matthew Parsons

Tax
Myra Sutanto Shen
Anjali Krishnan

Delaware Law
Ryan Greecher
Allurie Kephart
Ryan Hart

For more information, please see Silk Road’s press release.